NovoCure News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.04.22	Novocure to Report First Quarter 2022 Financial Results (Businesswire)
24.03.22	Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial (Businesswire)
23.03.22	Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer (Businesswire)
28.02.22	Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation (Businesswire)
24.02.22	Novocure’s General Counsel Resigns After 10 Years of Service (Businesswire)
24.02.22	New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response (Businesswire)
24.02.22	Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update (Businesswire)
10.01.22	Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update (Businesswire)
04.01.22	Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference (Businesswire)
01.07.21	Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer (Businesswire)
16.06.21	Novocure Initiates Usability Study for Flexible Torso Array (Businesswire)
25.05.21	Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma (Businesswire)
18.05.21	Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer (Businesswire)
29.04.21	Novocure Reports First Quarter 2021 Financial Results and Provides Company Update (Businesswire)
22.04.21	Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer (Businesswire)
15.04.21	Novocure gibt neueste Entwicklungen in der zulassungsrelevanten Phase-3-Studie LUNAR zu Tumor Treating Fields bei nicht-kleinzelligem Lungenkarzinom bekannt (Businesswire)
13.04.21	Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer (Businesswire)
09.04.21	Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields (Businesswire)
01.04.21	Novocure to Report First Quarter 2021 Financial Results (Businesswire)
25.02.21	Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update (Businesswire)
08.02.21	Novocure Announces Addition to Its Board of Directors (Businesswire)
11.01.21	Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update (Businesswire)
23.12.20	Novocure to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference (Businesswire)
14.12.20	Novocure meldet nationale Kostenübernahme in der Schweiz für Optune® in Kombination mit Temozolomid zur Behandlung von neu diagnostiziertem Glioblastom (Businesswire)
14.12.20	Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (Businesswire)
10.12.20	First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma (Businesswire)
25.11.20	Novocure to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference (Businesswire)
19.11.20	Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting (Businesswire)
16.11.20	Prüfungsausschuss beschliesst Erstattung medizinischer Leistungen für Behandlung mit Tumor-Therapie-Feldern in Deutschland (Businesswire)
11.11.20	Novocure Receives CE Mark for NovoTTF-100L™ System (Businesswire)
10.11.20	Novocure Announces Agenda for Virtual Research and Development Day (Businesswire)
09.11.20	Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks (Businesswire)
05.11.20	Novocure Announces Closing of $575 Million 0% Convertible Senior Notes Private Placement (Businesswire)
03.11.20	Novocure Prices $500 Million 0% Convertible Senior Notes Private Placement (Businesswire)
02.11.20	Novocure Announces Proposed Private Placement of $500 Million of Convertible Senior Notes (Businesswire)
29.10.20	Novocure Reports Third Quarter 2020 Financial Results and Provides Company Update (Businesswire)
29.10.20	Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical Research (Businesswire)
02.10.20	Novocure to Report Third Quarter 2020 Financial Results (Businesswire)
29.09.20	Novocure to Host Virtual Research & Development Day (Businesswire)
25.09.20	Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community (Businesswire)
04.09.20	Novocure to Participate in the 2020 Wells Fargo Virtual Healthcare Conference (Businesswire)
13.08.20	Novocure Announces Expansion of Its Executive Leadership Team (Businesswire)
30.07.20	Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update (Businesswire)
28.07.20	Novocure Announces Recipients of 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program (Businesswire)
22.07.20	First Patient Enrolled in Novocure’s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays (Businesswire)
15.07.20	Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer (Businesswire)
08.07.20	Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™ (Businesswire)
07.07.20	Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer (Businesswire)
01.07.20	Novocure to Report Second Quarter 2020 Financial Results (Businesswire)
02.06.20	Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Lonza Grp	548.20	4.94 %	K V
CieFinRichemont	135.60	1.46 %	K V
UBS Group	28.62	1.13 %	K V
Holcim	90.18	1.08 %	K V
Alcon	76.56	0.63 %	K V
Swiss Re	127.80	-0.31 %	K V
Sika	230.60	-0.60 %	K V
Swiss Life Hldg	687.20	-0.66 %	K V
Part Grp Hldg	1’284.50	-0.96 %	K V
Kuehne+Nagel Int	205.00	-2.80 %	K V

Nachrichten zu NovoCure Limited

Aktien Top/Flop

Meistgelesene Nachrichten